nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—ADRB2—prostate cancer	0.228	0.646	CbGaD
Cabergoline—CYP3A4—prostate cancer	0.125	0.354	CbGaD
Cabergoline—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0386	0.207	CbGbCtD
Cabergoline—ADRA1B—vas deferens—prostate cancer	0.023	0.35	CbGeAlD
Cabergoline—CYP3A4—Bicalutamide—prostate cancer	0.0203	0.109	CbGbCtD
Cabergoline—CYP3A4—Estramustine—prostate cancer	0.0188	0.101	CbGbCtD
Cabergoline—CYP3A4—Flutamide—prostate cancer	0.0168	0.09	CbGbCtD
Cabergoline—CYP3A4—Abiraterone—prostate cancer	0.0168	0.09	CbGbCtD
Cabergoline—HTR7—vas deferens—prostate cancer	0.0134	0.204	CbGeAlD
Cabergoline—CYP3A4—Cabazitaxel—prostate cancer	0.0124	0.0666	CbGbCtD
Cabergoline—CYP3A4—Estrone—prostate cancer	0.0121	0.0651	CbGbCtD
Cabergoline—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0108	0.058	CbGbCtD
Cabergoline—CYP3A4—Conjugated Estrogens—prostate cancer	0.00794	0.0426	CbGbCtD
Cabergoline—CYP3A4—Mitoxantrone—prostate cancer	0.00722	0.0387	CbGbCtD
Cabergoline—CYP3A4—Estradiol—prostate cancer	0.00697	0.0374	CbGbCtD
Cabergoline—CYP3A4—Prednisone—prostate cancer	0.006	0.0321	CbGbCtD
Cabergoline—CYP3A4—Etoposide—prostate cancer	0.00455	0.0244	CbGbCtD
Cabergoline—CYP3A4—Docetaxel—prostate cancer	0.00416	0.0223	CbGbCtD
Cabergoline—CYP3A4—Doxorubicin—prostate cancer	0.0031	0.0166	CbGbCtD
Cabergoline—HTR2A—urine—prostate cancer	0.00208	0.0317	CbGeAlD
Cabergoline—ADRA1D—prostate gland—prostate cancer	0.00201	0.0306	CbGeAlD
Cabergoline—CYP3A4—urine—prostate cancer	0.00192	0.0293	CbGeAlD
Cabergoline—DRD4—testis—prostate cancer	0.00167	0.0255	CbGeAlD
Cabergoline—ADRA1D—epithelium—prostate cancer	0.00148	0.0225	CbGeAlD
Cabergoline—ADRB1—prostate gland—prostate cancer	0.00146	0.0222	CbGeAlD
Cabergoline—ADRA1B—renal system—prostate cancer	0.0014	0.0213	CbGeAlD
Cabergoline—ADRA1D—urethra—prostate cancer	0.00134	0.0205	CbGeAlD
Cabergoline—ADRA1A—prostate gland—prostate cancer	0.00115	0.0176	CbGeAlD
Cabergoline—ADRA2C—prostate gland—prostate cancer	0.0011	0.0167	CbGeAlD
Cabergoline—ADRA2C—seminal vesicle—prostate cancer	0.00093	0.0142	CbGeAlD
Cabergoline—HTR7—epithelium—prostate cancer	0.000879	0.0134	CbGeAlD
Cabergoline—ADRA2A—prostate gland—prostate cancer	0.000877	0.0134	CbGeAlD
Cabergoline—HTR1A—renal system—prostate cancer	0.000853	0.013	CbGeAlD
Cabergoline—ADRA1A—epithelium—prostate cancer	0.000847	0.0129	CbGeAlD
Cabergoline—HTR7—renal system—prostate cancer	0.000815	0.0124	CbGeAlD
Cabergoline—ADRA1A—renal system—prostate cancer	0.000786	0.012	CbGeAlD
Cabergoline—ADRA2C—renal system—prostate cancer	0.000749	0.0114	CbGeAlD
Cabergoline—ADRA2A—seminal vesicle—prostate cancer	0.000742	0.0113	CbGeAlD
Cabergoline—ADRA2C—urethra—prostate cancer	0.000736	0.0112	CbGeAlD
Cabergoline—ADRA2A—urethra—prostate cancer	0.000587	0.00895	CbGeAlD
Cabergoline—HTR2A—epithelium—prostate cancer	0.000548	0.00835	CbGeAlD
Cabergoline—HTR7—testis—prostate cancer	0.000527	0.00803	CbGeAlD
Cabergoline—HTR2A—renal system—prostate cancer	0.000508	0.00774	CbGeAlD
Cabergoline—DRD2—testis—prostate cancer	0.000498	0.00759	CbGeAlD
Cabergoline—ADRA2C—testis—prostate cancer	0.000484	0.00738	CbGeAlD
Cabergoline—CYP3A4—renal system—prostate cancer	0.00047	0.00717	CbGeAlD
Cabergoline—HTR2B—lymph node—prostate cancer	0.000446	0.00679	CbGeAlD
Cabergoline—ADRA2A—testis—prostate cancer	0.000386	0.00589	CbGeAlD
Cabergoline—ADRA2C—lymph node—prostate cancer	0.000351	0.00535	CbGeAlD
Cabergoline—HTR2A—testis—prostate cancer	0.000328	0.00501	CbGeAlD
Cabergoline—ADRA2A—lymph node—prostate cancer	0.00028	0.00427	CbGeAlD
Cabergoline—Weight decreased—Epirubicin—prostate cancer	9.33e-05	0.00036	CcSEcCtD
Cabergoline—Dyspnoea—Etoposide—prostate cancer	9.33e-05	0.00036	CcSEcCtD
Cabergoline—Alopecia—Prednisone—prostate cancer	9.33e-05	0.00036	CcSEcCtD
Cabergoline—Malaise—Capecitabine—prostate cancer	9.3e-05	0.000359	CcSEcCtD
Cabergoline—Somnolence—Etoposide—prostate cancer	9.3e-05	0.000359	CcSEcCtD
Cabergoline—Vertigo—Capecitabine—prostate cancer	9.27e-05	0.000358	CcSEcCtD
Cabergoline—Hypersensitivity—Mitoxantrone—prostate cancer	9.27e-05	0.000358	CcSEcCtD
Cabergoline—Syncope—Capecitabine—prostate cancer	9.25e-05	0.000357	CcSEcCtD
Cabergoline—Pneumonia—Epirubicin—prostate cancer	9.25e-05	0.000357	CcSEcCtD
Cabergoline—Diarrhoea—Estradiol—prostate cancer	9.24e-05	0.000356	CcSEcCtD
Cabergoline—Hypertension—Docetaxel—prostate cancer	9.2e-05	0.000355	CcSEcCtD
Cabergoline—Bronchitis—Doxorubicin—prostate cancer	9.18e-05	0.000354	CcSEcCtD
Cabergoline—Palpitations—Capecitabine—prostate cancer	9.12e-05	0.000352	CcSEcCtD
Cabergoline—Decreased appetite—Etoposide—prostate cancer	9.1e-05	0.000351	CcSEcCtD
Cabergoline—Arthralgia—Docetaxel—prostate cancer	9.07e-05	0.00035	CcSEcCtD
Cabergoline—Loss of consciousness—Capecitabine—prostate cancer	9.07e-05	0.00035	CcSEcCtD
Cabergoline—Asthenia—Mitoxantrone—prostate cancer	9.03e-05	0.000348	CcSEcCtD
Cabergoline—Fatigue—Etoposide—prostate cancer	9.02e-05	0.000348	CcSEcCtD
Cabergoline—Pain—Etoposide—prostate cancer	8.95e-05	0.000345	CcSEcCtD
Cabergoline—Constipation—Etoposide—prostate cancer	8.95e-05	0.000345	CcSEcCtD
Cabergoline—Urinary tract infection—Epirubicin—prostate cancer	8.94e-05	0.000345	CcSEcCtD
Cabergoline—Dizziness—Estradiol—prostate cancer	8.93e-05	0.000344	CcSEcCtD
Cabergoline—Hypertension—Capecitabine—prostate cancer	8.91e-05	0.000344	CcSEcCtD
Cabergoline—Dry mouth—Docetaxel—prostate cancer	8.87e-05	0.000342	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Doxorubicin—prostate cancer	8.87e-05	0.000342	CcSEcCtD
Cabergoline—Arthralgia—Capecitabine—prostate cancer	8.78e-05	0.000339	CcSEcCtD
Cabergoline—Confusional state—Docetaxel—prostate cancer	8.77e-05	0.000338	CcSEcCtD
Cabergoline—Anxiety—Capecitabine—prostate cancer	8.75e-05	0.000338	CcSEcCtD
Cabergoline—Oedema—Docetaxel—prostate cancer	8.7e-05	0.000336	CcSEcCtD
Cabergoline—Weight increased—Doxorubicin—prostate cancer	8.69e-05	0.000335	CcSEcCtD
Cabergoline—Discomfort—Capecitabine—prostate cancer	8.68e-05	0.000335	CcSEcCtD
Cabergoline—Epistaxis—Epirubicin—prostate cancer	8.67e-05	0.000335	CcSEcCtD
Cabergoline—Weight decreased—Doxorubicin—prostate cancer	8.63e-05	0.000333	CcSEcCtD
Cabergoline—Feeling abnormal—Etoposide—prostate cancer	8.62e-05	0.000333	CcSEcCtD
Cabergoline—Diarrhoea—Mitoxantrone—prostate cancer	8.61e-05	0.000332	CcSEcCtD
Cabergoline—Dry mouth—Capecitabine—prostate cancer	8.59e-05	0.000331	CcSEcCtD
Cabergoline—Vomiting—Estradiol—prostate cancer	8.58e-05	0.000331	CcSEcCtD
Cabergoline—Pneumonia—Doxorubicin—prostate cancer	8.56e-05	0.00033	CcSEcCtD
Cabergoline—Gastrointestinal pain—Etoposide—prostate cancer	8.56e-05	0.00033	CcSEcCtD
Cabergoline—Shock—Docetaxel—prostate cancer	8.56e-05	0.00033	CcSEcCtD
Cabergoline—Ill-defined disorder—Prednisone—prostate cancer	8.53e-05	0.000329	CcSEcCtD
Cabergoline—Rash—Estradiol—prostate cancer	8.51e-05	0.000328	CcSEcCtD
Cabergoline—Dermatitis—Estradiol—prostate cancer	8.51e-05	0.000328	CcSEcCtD
Cabergoline—Confusional state—Capecitabine—prostate cancer	8.49e-05	0.000328	CcSEcCtD
Cabergoline—Headache—Estradiol—prostate cancer	8.46e-05	0.000326	CcSEcCtD
Cabergoline—Oedema—Capecitabine—prostate cancer	8.42e-05	0.000325	CcSEcCtD
Cabergoline—Anorexia—Docetaxel—prostate cancer	8.29e-05	0.00032	CcSEcCtD
Cabergoline—Malaise—Prednisone—prostate cancer	8.29e-05	0.00032	CcSEcCtD
Cabergoline—Shock—Capecitabine—prostate cancer	8.28e-05	0.00032	CcSEcCtD
Cabergoline—Rhinitis—Epirubicin—prostate cancer	8.28e-05	0.000319	CcSEcCtD
Cabergoline—Abdominal pain—Etoposide—prostate cancer	8.27e-05	0.000319	CcSEcCtD
Cabergoline—Urinary tract infection—Doxorubicin—prostate cancer	8.27e-05	0.000319	CcSEcCtD
Cabergoline—Vertigo—Prednisone—prostate cancer	8.26e-05	0.000319	CcSEcCtD
Cabergoline—Syncope—Prednisone—prostate cancer	8.24e-05	0.000318	CcSEcCtD
Cabergoline—Hyperhidrosis—Capecitabine—prostate cancer	8.14e-05	0.000314	CcSEcCtD
Cabergoline—Oedema peripheral—Epirubicin—prostate cancer	8.13e-05	0.000314	CcSEcCtD
Cabergoline—Hypotension—Docetaxel—prostate cancer	8.13e-05	0.000314	CcSEcCtD
Cabergoline—Loss of consciousness—Prednisone—prostate cancer	8.08e-05	0.000312	CcSEcCtD
Cabergoline—Epistaxis—Doxorubicin—prostate cancer	8.03e-05	0.00031	CcSEcCtD
Cabergoline—Anorexia—Capecitabine—prostate cancer	8.03e-05	0.00031	CcSEcCtD
Cabergoline—Nausea—Estradiol—prostate cancer	8.02e-05	0.000309	CcSEcCtD
Cabergoline—Vomiting—Mitoxantrone—prostate cancer	8e-05	0.000309	CcSEcCtD
Cabergoline—Visual impairment—Epirubicin—prostate cancer	7.96e-05	0.000307	CcSEcCtD
Cabergoline—Hypertension—Prednisone—prostate cancer	7.93e-05	0.000306	CcSEcCtD
Cabergoline—Rash—Mitoxantrone—prostate cancer	7.93e-05	0.000306	CcSEcCtD
Cabergoline—Dermatitis—Mitoxantrone—prostate cancer	7.92e-05	0.000306	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Docetaxel—prostate cancer	7.92e-05	0.000306	CcSEcCtD
Cabergoline—Headache—Mitoxantrone—prostate cancer	7.88e-05	0.000304	CcSEcCtD
Cabergoline—Hypotension—Capecitabine—prostate cancer	7.87e-05	0.000304	CcSEcCtD
Cabergoline—Insomnia—Docetaxel—prostate cancer	7.87e-05	0.000303	CcSEcCtD
Cabergoline—Arthralgia—Prednisone—prostate cancer	7.82e-05	0.000302	CcSEcCtD
Cabergoline—Paraesthesia—Docetaxel—prostate cancer	7.81e-05	0.000301	CcSEcCtD
Cabergoline—Anxiety—Prednisone—prostate cancer	7.8e-05	0.000301	CcSEcCtD
Cabergoline—Dyspnoea—Docetaxel—prostate cancer	7.75e-05	0.000299	CcSEcCtD
Cabergoline—Somnolence—Docetaxel—prostate cancer	7.73e-05	0.000298	CcSEcCtD
Cabergoline—Discomfort—Prednisone—prostate cancer	7.73e-05	0.000298	CcSEcCtD
Cabergoline—Hypersensitivity—Etoposide—prostate cancer	7.71e-05	0.000297	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Capecitabine—prostate cancer	7.67e-05	0.000296	CcSEcCtD
Cabergoline—Cardiac disorder—Epirubicin—prostate cancer	7.66e-05	0.000296	CcSEcCtD
Cabergoline—Rhinitis—Doxorubicin—prostate cancer	7.66e-05	0.000295	CcSEcCtD
Cabergoline—Dyspepsia—Docetaxel—prostate cancer	7.66e-05	0.000295	CcSEcCtD
Cabergoline—Insomnia—Capecitabine—prostate cancer	7.62e-05	0.000294	CcSEcCtD
Cabergoline—Paraesthesia—Capecitabine—prostate cancer	7.56e-05	0.000292	CcSEcCtD
Cabergoline—Decreased appetite—Docetaxel—prostate cancer	7.56e-05	0.000292	CcSEcCtD
Cabergoline—Oedema peripheral—Doxorubicin—prostate cancer	7.53e-05	0.00029	CcSEcCtD
Cabergoline—Asthenia—Etoposide—prostate cancer	7.51e-05	0.00029	CcSEcCtD
Cabergoline—Dyspnoea—Capecitabine—prostate cancer	7.51e-05	0.00029	CcSEcCtD
Cabergoline—Oedema—Prednisone—prostate cancer	7.5e-05	0.000289	CcSEcCtD
Cabergoline—Fatigue—Docetaxel—prostate cancer	7.5e-05	0.000289	CcSEcCtD
Cabergoline—Nausea—Mitoxantrone—prostate cancer	7.47e-05	0.000288	CcSEcCtD
Cabergoline—Constipation—Docetaxel—prostate cancer	7.44e-05	0.000287	CcSEcCtD
Cabergoline—Pain—Docetaxel—prostate cancer	7.44e-05	0.000287	CcSEcCtD
Cabergoline—Dyspepsia—Capecitabine—prostate cancer	7.41e-05	0.000286	CcSEcCtD
Cabergoline—Pruritus—Etoposide—prostate cancer	7.4e-05	0.000286	CcSEcCtD
Cabergoline—Shock—Prednisone—prostate cancer	7.38e-05	0.000285	CcSEcCtD
Cabergoline—Arrhythmia—Epirubicin—prostate cancer	7.38e-05	0.000285	CcSEcCtD
Cabergoline—Visual impairment—Doxorubicin—prostate cancer	7.36e-05	0.000284	CcSEcCtD
Cabergoline—Decreased appetite—Capecitabine—prostate cancer	7.32e-05	0.000282	CcSEcCtD
Cabergoline—Alopecia—Epirubicin—prostate cancer	7.3e-05	0.000281	CcSEcCtD
Cabergoline—Fatigue—Capecitabine—prostate cancer	7.26e-05	0.00028	CcSEcCtD
Cabergoline—Hyperhidrosis—Prednisone—prostate cancer	7.25e-05	0.00028	CcSEcCtD
Cabergoline—Pain—Capecitabine—prostate cancer	7.2e-05	0.000278	CcSEcCtD
Cabergoline—Constipation—Capecitabine—prostate cancer	7.2e-05	0.000278	CcSEcCtD
Cabergoline—Feeling abnormal—Docetaxel—prostate cancer	7.17e-05	0.000276	CcSEcCtD
Cabergoline—Diarrhoea—Etoposide—prostate cancer	7.16e-05	0.000276	CcSEcCtD
Cabergoline—Anorexia—Prednisone—prostate cancer	7.15e-05	0.000276	CcSEcCtD
Cabergoline—Gastrointestinal pain—Docetaxel—prostate cancer	7.11e-05	0.000274	CcSEcCtD
Cabergoline—Cardiac disorder—Doxorubicin—prostate cancer	7.09e-05	0.000274	CcSEcCtD
Cabergoline—Flatulence—Epirubicin—prostate cancer	7.08e-05	0.000273	CcSEcCtD
Cabergoline—Tension—Epirubicin—prostate cancer	7.05e-05	0.000272	CcSEcCtD
Cabergoline—Nervousness—Epirubicin—prostate cancer	6.98e-05	0.000269	CcSEcCtD
Cabergoline—Back pain—Epirubicin—prostate cancer	6.95e-05	0.000268	CcSEcCtD
Cabergoline—Feeling abnormal—Capecitabine—prostate cancer	6.94e-05	0.000268	CcSEcCtD
Cabergoline—Dizziness—Etoposide—prostate cancer	6.92e-05	0.000267	CcSEcCtD
Cabergoline—Muscle spasms—Epirubicin—prostate cancer	6.91e-05	0.000267	CcSEcCtD
Cabergoline—Gastrointestinal pain—Capecitabine—prostate cancer	6.89e-05	0.000266	CcSEcCtD
Cabergoline—Abdominal pain—Docetaxel—prostate cancer	6.87e-05	0.000265	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Prednisone—prostate cancer	6.83e-05	0.000264	CcSEcCtD
Cabergoline—Arrhythmia—Doxorubicin—prostate cancer	6.82e-05	0.000263	CcSEcCtD
Cabergoline—Pergolide—CYP3A4—prostate cancer	6.79e-05	0.535	CrCbGaD
Cabergoline—Insomnia—Prednisone—prostate cancer	6.78e-05	0.000262	CcSEcCtD
Cabergoline—Alopecia—Doxorubicin—prostate cancer	6.75e-05	0.00026	CcSEcCtD
Cabergoline—Paraesthesia—Prednisone—prostate cancer	6.73e-05	0.00026	CcSEcCtD
Cabergoline—Ill-defined disorder—Epirubicin—prostate cancer	6.67e-05	0.000257	CcSEcCtD
Cabergoline—Abdominal pain—Capecitabine—prostate cancer	6.66e-05	0.000257	CcSEcCtD
Cabergoline—Vomiting—Etoposide—prostate cancer	6.65e-05	0.000257	CcSEcCtD
Cabergoline—Dyspepsia—Prednisone—prostate cancer	6.6e-05	0.000255	CcSEcCtD
Cabergoline—Rash—Etoposide—prostate cancer	6.6e-05	0.000255	CcSEcCtD
Cabergoline—Dermatitis—Etoposide—prostate cancer	6.59e-05	0.000254	CcSEcCtD
Cabergoline—Headache—Etoposide—prostate cancer	6.56e-05	0.000253	CcSEcCtD
Cabergoline—Flatulence—Doxorubicin—prostate cancer	6.55e-05	0.000253	CcSEcCtD
Cabergoline—Tension—Doxorubicin—prostate cancer	6.53e-05	0.000252	CcSEcCtD
Cabergoline—Decreased appetite—Prednisone—prostate cancer	6.52e-05	0.000252	CcSEcCtD
Cabergoline—Malaise—Epirubicin—prostate cancer	6.48e-05	0.00025	CcSEcCtD
Cabergoline—Fatigue—Prednisone—prostate cancer	6.47e-05	0.000249	CcSEcCtD
Cabergoline—Nervousness—Doxorubicin—prostate cancer	6.46e-05	0.000249	CcSEcCtD
Cabergoline—Vertigo—Epirubicin—prostate cancer	6.46e-05	0.000249	CcSEcCtD
Cabergoline—Syncope—Epirubicin—prostate cancer	6.45e-05	0.000249	CcSEcCtD
Cabergoline—Back pain—Doxorubicin—prostate cancer	6.43e-05	0.000248	CcSEcCtD
Cabergoline—Constipation—Prednisone—prostate cancer	6.41e-05	0.000247	CcSEcCtD
Cabergoline—Hypersensitivity—Docetaxel—prostate cancer	6.41e-05	0.000247	CcSEcCtD
Cabergoline—Muscle spasms—Doxorubicin—prostate cancer	6.39e-05	0.000247	CcSEcCtD
Cabergoline—Palpitations—Epirubicin—prostate cancer	6.35e-05	0.000245	CcSEcCtD
Cabergoline—Loss of consciousness—Epirubicin—prostate cancer	6.32e-05	0.000244	CcSEcCtD
Cabergoline—Asthenia—Docetaxel—prostate cancer	6.24e-05	0.000241	CcSEcCtD
Cabergoline—Nausea—Etoposide—prostate cancer	6.22e-05	0.00024	CcSEcCtD
Cabergoline—Hypertension—Epirubicin—prostate cancer	6.21e-05	0.000239	CcSEcCtD
Cabergoline—Hypersensitivity—Capecitabine—prostate cancer	6.2e-05	0.000239	CcSEcCtD
Cabergoline—Feeling abnormal—Prednisone—prostate cancer	6.18e-05	0.000238	CcSEcCtD
Cabergoline—Ill-defined disorder—Doxorubicin—prostate cancer	6.17e-05	0.000238	CcSEcCtD
Cabergoline—Pruritus—Docetaxel—prostate cancer	6.15e-05	0.000237	CcSEcCtD
Cabergoline—Gastrointestinal pain—Prednisone—prostate cancer	6.13e-05	0.000237	CcSEcCtD
Cabergoline—Arthralgia—Epirubicin—prostate cancer	6.12e-05	0.000236	CcSEcCtD
Cabergoline—Anxiety—Epirubicin—prostate cancer	6.1e-05	0.000235	CcSEcCtD
Cabergoline—Discomfort—Epirubicin—prostate cancer	6.05e-05	0.000233	CcSEcCtD
Cabergoline—Asthenia—Capecitabine—prostate cancer	6.04e-05	0.000233	CcSEcCtD
Cabergoline—Malaise—Doxorubicin—prostate cancer	6e-05	0.000231	CcSEcCtD
Cabergoline—Dry mouth—Epirubicin—prostate cancer	5.98e-05	0.000231	CcSEcCtD
Cabergoline—Vertigo—Doxorubicin—prostate cancer	5.97e-05	0.000231	CcSEcCtD
Cabergoline—Syncope—Doxorubicin—prostate cancer	5.96e-05	0.00023	CcSEcCtD
Cabergoline—Pruritus—Capecitabine—prostate cancer	5.96e-05	0.00023	CcSEcCtD
Cabergoline—Diarrhoea—Docetaxel—prostate cancer	5.95e-05	0.00023	CcSEcCtD
Cabergoline—Abdominal pain—Prednisone—prostate cancer	5.93e-05	0.000229	CcSEcCtD
Cabergoline—Confusional state—Epirubicin—prostate cancer	5.91e-05	0.000228	CcSEcCtD
Cabergoline—Lisuride—CYP3A4—prostate cancer	5.9e-05	0.465	CrCbGaD
Cabergoline—Palpitations—Doxorubicin—prostate cancer	5.88e-05	0.000227	CcSEcCtD
Cabergoline—Oedema—Epirubicin—prostate cancer	5.87e-05	0.000226	CcSEcCtD
Cabergoline—Loss of consciousness—Doxorubicin—prostate cancer	5.84e-05	0.000225	CcSEcCtD
Cabergoline—Shock—Epirubicin—prostate cancer	5.77e-05	0.000223	CcSEcCtD
Cabergoline—Diarrhoea—Capecitabine—prostate cancer	5.76e-05	0.000222	CcSEcCtD
Cabergoline—Dizziness—Docetaxel—prostate cancer	5.75e-05	0.000222	CcSEcCtD
Cabergoline—Hypertension—Doxorubicin—prostate cancer	5.74e-05	0.000222	CcSEcCtD
Cabergoline—Hyperhidrosis—Epirubicin—prostate cancer	5.67e-05	0.000219	CcSEcCtD
Cabergoline—Arthralgia—Doxorubicin—prostate cancer	5.66e-05	0.000218	CcSEcCtD
Cabergoline—Anxiety—Doxorubicin—prostate cancer	5.64e-05	0.000218	CcSEcCtD
Cabergoline—Discomfort—Doxorubicin—prostate cancer	5.59e-05	0.000216	CcSEcCtD
Cabergoline—Anorexia—Epirubicin—prostate cancer	5.59e-05	0.000216	CcSEcCtD
Cabergoline—Dizziness—Capecitabine—prostate cancer	5.57e-05	0.000215	CcSEcCtD
Cabergoline—Dry mouth—Doxorubicin—prostate cancer	5.54e-05	0.000214	CcSEcCtD
Cabergoline—Vomiting—Docetaxel—prostate cancer	5.53e-05	0.000213	CcSEcCtD
Cabergoline—Hypersensitivity—Prednisone—prostate cancer	5.53e-05	0.000213	CcSEcCtD
Cabergoline—Rash—Docetaxel—prostate cancer	5.48e-05	0.000212	CcSEcCtD
Cabergoline—Hypotension—Epirubicin—prostate cancer	5.48e-05	0.000211	CcSEcCtD
Cabergoline—Dermatitis—Docetaxel—prostate cancer	5.48e-05	0.000211	CcSEcCtD
Cabergoline—Confusional state—Doxorubicin—prostate cancer	5.47e-05	0.000211	CcSEcCtD
Cabergoline—Headache—Docetaxel—prostate cancer	5.45e-05	0.00021	CcSEcCtD
Cabergoline—Oedema—Doxorubicin—prostate cancer	5.43e-05	0.000209	CcSEcCtD
Cabergoline—Asthenia—Prednisone—prostate cancer	5.38e-05	0.000208	CcSEcCtD
Cabergoline—Vomiting—Capecitabine—prostate cancer	5.35e-05	0.000207	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.34e-05	0.000206	CcSEcCtD
Cabergoline—Shock—Doxorubicin—prostate cancer	5.34e-05	0.000206	CcSEcCtD
Cabergoline—Rash—Capecitabine—prostate cancer	5.31e-05	0.000205	CcSEcCtD
Cabergoline—Pruritus—Prednisone—prostate cancer	5.31e-05	0.000205	CcSEcCtD
Cabergoline—Insomnia—Epirubicin—prostate cancer	5.31e-05	0.000205	CcSEcCtD
Cabergoline—Dermatitis—Capecitabine—prostate cancer	5.3e-05	0.000205	CcSEcCtD
Cabergoline—Headache—Capecitabine—prostate cancer	5.27e-05	0.000203	CcSEcCtD
Cabergoline—Paraesthesia—Epirubicin—prostate cancer	5.27e-05	0.000203	CcSEcCtD
Cabergoline—Hyperhidrosis—Doxorubicin—prostate cancer	5.25e-05	0.000202	CcSEcCtD
Cabergoline—Dyspnoea—Epirubicin—prostate cancer	5.23e-05	0.000202	CcSEcCtD
Cabergoline—Somnolence—Epirubicin—prostate cancer	5.21e-05	0.000201	CcSEcCtD
Cabergoline—Anorexia—Doxorubicin—prostate cancer	5.17e-05	0.0002	CcSEcCtD
Cabergoline—Nausea—Docetaxel—prostate cancer	5.17e-05	0.000199	CcSEcCtD
Cabergoline—Dyspepsia—Epirubicin—prostate cancer	5.16e-05	0.000199	CcSEcCtD
Cabergoline—Diarrhoea—Prednisone—prostate cancer	5.13e-05	0.000198	CcSEcCtD
Cabergoline—Decreased appetite—Epirubicin—prostate cancer	5.1e-05	0.000197	CcSEcCtD
Cabergoline—Hypotension—Doxorubicin—prostate cancer	5.07e-05	0.000196	CcSEcCtD
Cabergoline—Fatigue—Epirubicin—prostate cancer	5.06e-05	0.000195	CcSEcCtD
Cabergoline—Pain—Epirubicin—prostate cancer	5.02e-05	0.000194	CcSEcCtD
Cabergoline—Constipation—Epirubicin—prostate cancer	5.02e-05	0.000194	CcSEcCtD
Cabergoline—Nausea—Capecitabine—prostate cancer	5e-05	0.000193	CcSEcCtD
Cabergoline—Dizziness—Prednisone—prostate cancer	4.96e-05	0.000191	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.94e-05	0.000191	CcSEcCtD
Cabergoline—Insomnia—Doxorubicin—prostate cancer	4.91e-05	0.000189	CcSEcCtD
Cabergoline—Paraesthesia—Doxorubicin—prostate cancer	4.87e-05	0.000188	CcSEcCtD
Cabergoline—Dyspnoea—Doxorubicin—prostate cancer	4.84e-05	0.000187	CcSEcCtD
Cabergoline—Feeling abnormal—Epirubicin—prostate cancer	4.83e-05	0.000186	CcSEcCtD
Cabergoline—Somnolence—Doxorubicin—prostate cancer	4.82e-05	0.000186	CcSEcCtD
Cabergoline—Gastrointestinal pain—Epirubicin—prostate cancer	4.8e-05	0.000185	CcSEcCtD
Cabergoline—Dyspepsia—Doxorubicin—prostate cancer	4.78e-05	0.000184	CcSEcCtD
Cabergoline—Vomiting—Prednisone—prostate cancer	4.77e-05	0.000184	CcSEcCtD
Cabergoline—Rash—Prednisone—prostate cancer	4.73e-05	0.000182	CcSEcCtD
Cabergoline—Dermatitis—Prednisone—prostate cancer	4.72e-05	0.000182	CcSEcCtD
Cabergoline—Decreased appetite—Doxorubicin—prostate cancer	4.72e-05	0.000182	CcSEcCtD
Cabergoline—Headache—Prednisone—prostate cancer	4.7e-05	0.000181	CcSEcCtD
Cabergoline—Fatigue—Doxorubicin—prostate cancer	4.68e-05	0.000181	CcSEcCtD
Cabergoline—Constipation—Doxorubicin—prostate cancer	4.64e-05	0.000179	CcSEcCtD
Cabergoline—Pain—Doxorubicin—prostate cancer	4.64e-05	0.000179	CcSEcCtD
Cabergoline—Abdominal pain—Epirubicin—prostate cancer	4.64e-05	0.000179	CcSEcCtD
Cabergoline—Feeling abnormal—Doxorubicin—prostate cancer	4.47e-05	0.000173	CcSEcCtD
Cabergoline—Nausea—Prednisone—prostate cancer	4.45e-05	0.000172	CcSEcCtD
Cabergoline—Gastrointestinal pain—Doxorubicin—prostate cancer	4.44e-05	0.000171	CcSEcCtD
Cabergoline—Hypersensitivity—Epirubicin—prostate cancer	4.32e-05	0.000167	CcSEcCtD
Cabergoline—Abdominal pain—Doxorubicin—prostate cancer	4.29e-05	0.000166	CcSEcCtD
Cabergoline—Asthenia—Epirubicin—prostate cancer	4.21e-05	0.000162	CcSEcCtD
Cabergoline—Pruritus—Epirubicin—prostate cancer	4.15e-05	0.00016	CcSEcCtD
Cabergoline—Diarrhoea—Epirubicin—prostate cancer	4.01e-05	0.000155	CcSEcCtD
Cabergoline—Hypersensitivity—Doxorubicin—prostate cancer	4e-05	0.000154	CcSEcCtD
Cabergoline—Asthenia—Doxorubicin—prostate cancer	3.89e-05	0.00015	CcSEcCtD
Cabergoline—Dizziness—Epirubicin—prostate cancer	3.88e-05	0.00015	CcSEcCtD
Cabergoline—Pruritus—Doxorubicin—prostate cancer	3.84e-05	0.000148	CcSEcCtD
Cabergoline—Vomiting—Epirubicin—prostate cancer	3.73e-05	0.000144	CcSEcCtD
Cabergoline—Diarrhoea—Doxorubicin—prostate cancer	3.71e-05	0.000143	CcSEcCtD
Cabergoline—Rash—Epirubicin—prostate cancer	3.7e-05	0.000143	CcSEcCtD
Cabergoline—Dermatitis—Epirubicin—prostate cancer	3.69e-05	0.000143	CcSEcCtD
Cabergoline—Headache—Epirubicin—prostate cancer	3.67e-05	0.000142	CcSEcCtD
Cabergoline—Dizziness—Doxorubicin—prostate cancer	3.59e-05	0.000138	CcSEcCtD
Cabergoline—Nausea—Epirubicin—prostate cancer	3.48e-05	0.000134	CcSEcCtD
Cabergoline—Vomiting—Doxorubicin—prostate cancer	3.45e-05	0.000133	CcSEcCtD
Cabergoline—Rash—Doxorubicin—prostate cancer	3.42e-05	0.000132	CcSEcCtD
Cabergoline—Dermatitis—Doxorubicin—prostate cancer	3.42e-05	0.000132	CcSEcCtD
Cabergoline—Headache—Doxorubicin—prostate cancer	3.4e-05	0.000131	CcSEcCtD
Cabergoline—Nausea—Doxorubicin—prostate cancer	3.22e-05	0.000124	CcSEcCtD
Cabergoline—ADRA1D—Signaling Pathways—MYC—prostate cancer	2.41e-06	1.78e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MYC—prostate cancer	2.41e-06	1.78e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PTEN—prostate cancer	2.41e-06	1.78e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—PIK3CA—prostate cancer	2.41e-06	1.78e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TGFB1—prostate cancer	2.41e-06	1.77e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	2.41e-06	1.77e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—EP300—prostate cancer	2.4e-06	1.77e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—SRC—prostate cancer	2.4e-06	1.77e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—KRAS—prostate cancer	2.39e-06	1.77e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	2.39e-06	1.76e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—EGFR—prostate cancer	2.39e-06	1.76e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—VEGFA—prostate cancer	2.39e-06	1.76e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	2.39e-06	1.76e-05	CbGpPWpGaD
Cabergoline—DRD2—GPCR downstream signaling—AKT1—prostate cancer	2.39e-06	1.76e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	2.38e-06	1.75e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PTEN—prostate cancer	2.38e-06	1.75e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	2.37e-06	1.75e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	2.37e-06	1.75e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	2.37e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—STAT3—prostate cancer	2.36e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MDM2—prostate cancer	2.36e-06	1.74e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CASP3—prostate cancer	2.36e-06	1.74e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL2—prostate cancer	2.36e-06	1.74e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—EGFR—prostate cancer	2.36e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—EGFR—prostate cancer	2.36e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	2.35e-06	1.73e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL6—prostate cancer	2.35e-06	1.73e-05	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	2.35e-06	1.73e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—SRC—prostate cancer	2.35e-06	1.73e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—STAT3—prostate cancer	2.34e-06	1.73e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	2.34e-06	1.73e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—RXRA—prostate cancer	2.34e-06	1.72e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—VEGFA—prostate cancer	2.34e-06	1.72e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EP300—prostate cancer	2.33e-06	1.72e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—SRC—prostate cancer	2.33e-06	1.72e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	2.33e-06	1.72e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—prostate cancer	2.33e-06	1.72e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CASP3—prostate cancer	2.33e-06	1.71e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	2.32e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL2—prostate cancer	2.32e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—prostate cancer	2.31e-06	1.71e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—STAT3—prostate cancer	2.31e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—prostate cancer	2.31e-06	1.7e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—PIK3CA—prostate cancer	2.3e-06	1.7e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCND1—prostate cancer	2.3e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	2.3e-06	1.7e-05	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	2.3e-06	1.69e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EP300—prostate cancer	2.3e-06	1.69e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—prostate cancer	2.28e-06	1.68e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CTNNB1—prostate cancer	2.28e-06	1.68e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CASP3—prostate cancer	2.28e-06	1.68e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL2—prostate cancer	2.27e-06	1.68e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—prostate cancer	2.27e-06	1.68e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—SRC—prostate cancer	2.27e-06	1.67e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—EP300—prostate cancer	2.27e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—prostate cancer	2.27e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCND1—prostate cancer	2.26e-06	1.67e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—prostate cancer	2.26e-06	1.67e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—STAT3—prostate cancer	2.26e-06	1.67e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—KRAS—prostate cancer	2.26e-06	1.67e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—COMT—prostate cancer	2.25e-06	1.66e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—STAT3—prostate cancer	2.25e-06	1.66e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	2.24e-06	1.65e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTP1—prostate cancer	2.24e-06	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—SRC—prostate cancer	2.23e-06	1.65e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MMP9—prostate cancer	2.23e-06	1.65e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—prostate cancer	2.23e-06	1.64e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—KRAS—prostate cancer	2.23e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—KRAS—prostate cancer	2.23e-06	1.64e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CDKN1A—prostate cancer	2.23e-06	1.64e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PTEN—prostate cancer	2.22e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCND1—prostate cancer	2.22e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	2.21e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	2.21e-06	1.63e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ITPR1—prostate cancer	2.21e-06	1.63e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	2.2e-06	1.62e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MMP9—prostate cancer	2.2e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MYC—prostate cancer	2.2e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	2.19e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TGFB1—prostate cancer	2.19e-06	1.62e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	2.19e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—STAT3—prostate cancer	2.19e-06	1.61e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PTEN—prostate cancer	2.18e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MYC—prostate cancer	2.18e-06	1.61e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	2.18e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	2.17e-06	1.6e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—prostate cancer	2.17e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	2.16e-06	1.59e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—STAT3—prostate cancer	2.15e-06	1.59e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MMP9—prostate cancer	2.15e-06	1.59e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MYC—prostate cancer	2.15e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—EGFR—prostate cancer	2.15e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	2.14e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TGFB1—prostate cancer	2.14e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PTEN—prostate cancer	2.14e-06	1.58e-05	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	2.14e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—prostate cancer	2.13e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—prostate cancer	2.13e-06	1.57e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—EGFR—prostate cancer	2.13e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—prostate cancer	2.13e-06	1.57e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—prostate cancer	2.12e-06	1.56e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EP300—prostate cancer	2.12e-06	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CASP3—prostate cancer	2.12e-06	1.56e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL2—prostate cancer	2.11e-06	1.56e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—EGFR—prostate cancer	2.1e-06	1.55e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—prostate cancer	2.1e-06	1.55e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MYC—prostate cancer	2.1e-06	1.55e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TGFB1—prostate cancer	2.1e-06	1.55e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MYC—prostate cancer	2.09e-06	1.54e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	2.09e-06	1.54e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TGFB1—prostate cancer	2.09e-06	1.54e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—TYMS—prostate cancer	2.08e-06	1.54e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EP300—prostate cancer	2.08e-06	1.54e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—PIK3CA—prostate cancer	2.07e-06	1.53e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—prostate cancer	2.07e-06	1.53e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PIK3CA—prostate cancer	2.06e-06	1.52e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—GSTM1—prostate cancer	2.06e-06	1.52e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCND1—prostate cancer	2.06e-06	1.52e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—SRC—prostate cancer	2.06e-06	1.52e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—EGFR—prostate cancer	2.06e-06	1.52e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—PIK3CA—prostate cancer	2.05e-06	1.51e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	2.05e-06	1.51e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—EGFR—prostate cancer	2.04e-06	1.51e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—prostate cancer	2.04e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EP300—prostate cancer	2.04e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	2.04e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MYC—prostate cancer	2.03e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—KRAS—prostate cancer	2.03e-06	1.5e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	2.03e-06	1.5e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—SRC—prostate cancer	2.03e-06	1.49e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—LPL—prostate cancer	2.02e-06	1.49e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—KRAS—prostate cancer	2.01e-06	1.48e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—prostate cancer	2.01e-06	1.48e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—prostate cancer	2.01e-06	1.48e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MYC—prostate cancer	2e-06	1.48e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MMP9—prostate cancer	2e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	2e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	1.99e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EGFR—prostate cancer	1.99e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PTEN—prostate cancer	1.99e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—KRAS—prostate cancer	1.99e-06	1.46e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—STAT3—prostate cancer	1.99e-06	1.46e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SRC—prostate cancer	1.98e-06	1.46e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—prostate cancer	1.98e-06	1.46e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—prostate cancer	1.98e-06	1.46e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—prostate cancer	1.97e-06	1.46e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—prostate cancer	1.97e-06	1.45e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EGFR—prostate cancer	1.96e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—prostate cancer	1.95e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—STAT3—prostate cancer	1.95e-06	1.44e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.95e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—prostate cancer	1.95e-06	1.44e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—KRAS—prostate cancer	1.94e-06	1.43e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	1.94e-06	1.43e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ERCC2—prostate cancer	1.94e-06	1.43e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	1.93e-06	1.42e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—KRAS—prostate cancer	1.93e-06	1.42e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—STAT3—prostate cancer	1.91e-06	1.41e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—prostate cancer	1.91e-06	1.41e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EP300—prostate cancer	1.9e-06	1.4e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—prostate cancer	1.88e-06	1.39e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—KRAS—prostate cancer	1.88e-06	1.39e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	1.87e-06	1.38e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—KRAS—prostate cancer	1.85e-06	1.36e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	1.85e-06	1.36e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MYC—prostate cancer	1.85e-06	1.36e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SRC—prostate cancer	1.84e-06	1.36e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TGFB1—prostate cancer	1.84e-06	1.36e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—prostate cancer	1.84e-06	1.35e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	1.82e-06	1.35e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—MTHFR—prostate cancer	1.82e-06	1.34e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MYC—prostate cancer	1.82e-06	1.34e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—prostate cancer	1.81e-06	1.34e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—prostate cancer	1.81e-06	1.34e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TGFB1—prostate cancer	1.81e-06	1.34e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EGFR—prostate cancer	1.8e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—prostate cancer	1.8e-06	1.33e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—prostate cancer	1.8e-06	1.33e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	1.8e-06	1.32e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—prostate cancer	1.79e-06	1.32e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARA—prostate cancer	1.79e-06	1.32e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	1.78e-06	1.32e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MYC—prostate cancer	1.78e-06	1.31e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—STAT3—prostate cancer	1.78e-06	1.31e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EGFR—prostate cancer	1.78e-06	1.31e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	1.77e-06	1.31e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	1.77e-06	1.31e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—prostate cancer	1.77e-06	1.3e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EGFR—prostate cancer	1.74e-06	1.28e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	1.73e-06	1.27e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—prostate cancer	1.73e-06	1.27e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—prostate cancer	1.72e-06	1.27e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—KRAS—prostate cancer	1.7e-06	1.26e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	1.7e-06	1.25e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—prostate cancer	1.69e-06	1.25e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—prostate cancer	1.69e-06	1.24e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CAV1—prostate cancer	1.68e-06	1.24e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—KRAS—prostate cancer	1.68e-06	1.24e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.68e-06	1.24e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—prostate cancer	1.67e-06	1.23e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—prostate cancer	1.67e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—prostate cancer	1.67e-06	1.23e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.65e-06	1.22e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—prostate cancer	1.65e-06	1.22e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.65e-06	1.22e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—prostate cancer	1.64e-06	1.21e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—KRAS—prostate cancer	1.64e-06	1.21e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—prostate cancer	1.64e-06	1.21e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—prostate cancer	1.62e-06	1.19e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.62e-06	1.19e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—prostate cancer	1.58e-06	1.16e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—prostate cancer	1.57e-06	1.16e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PIK3CA—prostate cancer	1.57e-06	1.16e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	1.54e-06	1.14e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.53e-06	1.13e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—prostate cancer	1.53e-06	1.13e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.53e-06	1.13e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—prostate cancer	1.52e-06	1.12e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—prostate cancer	1.52e-06	1.12e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—prostate cancer	1.51e-06	1.11e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	1.51e-06	1.11e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—prostate cancer	1.5e-06	1.11e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—prostate cancer	1.49e-06	1.1e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—prostate cancer	1.49e-06	1.1e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—prostate cancer	1.46e-06	1.08e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—prostate cancer	1.46e-06	1.07e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—prostate cancer	1.45e-06	1.07e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—INS—prostate cancer	1.45e-06	1.07e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CREBBP—prostate cancer	1.42e-06	1.05e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—prostate cancer	1.41e-06	1.04e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	1.4e-06	1.03e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—prostate cancer	1.39e-06	1.02e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—prostate cancer	1.39e-06	1.02e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—prostate cancer	1.37e-06	1.01e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—prostate cancer	1.36e-06	1.01e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—prostate cancer	1.36e-06	1e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.34e-06	9.91e-06	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—prostate cancer	1.34e-06	9.85e-06	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—prostate cancer	1.28e-06	9.44e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—NOS3—prostate cancer	1.27e-06	9.36e-06	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—prostate cancer	1.26e-06	9.28e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—prostate cancer	1.24e-06	9.16e-06	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—prostate cancer	1.23e-06	9.09e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.17e-06	8.64e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTGS2—prostate cancer	1.16e-06	8.56e-06	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—prostate cancer	1.15e-06	8.45e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTEN—prostate cancer	1.01e-06	7.47e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—EP300—prostate cancer	9.66e-07	7.12e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CA—prostate cancer	7.14e-07	5.27e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—prostate cancer	5.84e-07	4.3e-06	CbGpPWpGaD
